Haemophilia A

Roche extends until 2028 its commitment to the WFH Humanitarian Aid Program aimed at helping people with haemophilia

The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there…

2 years ago

Roche extiende hasta 2028 su compromiso con el Programa de ayuda humanitaria de la FMH destinado a ayudar a las personas con hemofilia

El compromiso renovado proporcionará tratamiento preventivo (profiláctico) continuo a hasta 1000 personas con hemofilia A en lugares donde hay poco o ningún…

2 years ago

Roche’s announces favourable safety profile and effective bleed control for its Hemlibra in people with moderate or mild haemophilia A without factor VIII inhibitors

People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to…

2 years ago

Haemophilia A: data from Roche’s HAVEN 1 published in The New England Journal of Medicine (NEJM)

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1…

7 years ago